Mark Goodarzi is an Endocrinology/Metabolic physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8700 Beverly Blvd.
Los Angeles, CA 900481865
Telephone
310-423-4774Registry record last updated 6 Aug 2014.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year20241 payment
- Organon LLCProgram year20232 payments
- Nestle HealthCare Nutrition Inc.Program year20222 payments$12,000openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
62.1%GLP-1 receptor agonist17.9%Mounjaro67%Ozempic33%Part D<11 patientsBiguanide (metformin)14.3%Metformin Hcl Er53%Metformin Hcl47%Part D≥14 patients+ 3 more classes in this area
Hormonal (systemic)
19.5%l-Thyroxine19.5%Levothyroxine Sodium52%Synthroid48%Part D<11 patientsCardiovascular
16.2%Statin6.9%Rosuvastatin Calcium52%Atorvastatin Calcium48%Part D<11 patientsThiazide-like diuretic3.6%Chlorthalidone100%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
6 NIH research awards on record, funded 2006–2026 per NIH RePORTER. The latest:
- Cedars Sinai Center for the Chronic Pancreatitis Clinical Research Consortium
Cedars-Sinai Medical Center
FY2026$554,442U01DK108314 - Cedars Sinai Clinical Center of the Type 1 Diabetes in Acute Pancreatitis Consortium
Cedars-Sinai Medical Center
FY2026$511,000U01DK127403 - Cedars Sinai Center for the Chronic Pancreatitis Clinical Research Consortium
Cedars-Sinai Medical Center
FY2025$574,090U01DK108314
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”